BR0213565A - Anticorpo de anti-tnf alfa modificado - Google Patents

Anticorpo de anti-tnf alfa modificado

Info

Publication number
BR0213565A
BR0213565A BR0213565-5A BR0213565A BR0213565A BR 0213565 A BR0213565 A BR 0213565A BR 0213565 A BR0213565 A BR 0213565A BR 0213565 A BR0213565 A BR 0213565A
Authority
BR
Brazil
Prior art keywords
alpha
tnf
modified
tnf antibody
antibody
Prior art date
Application number
BR0213565-5A
Other languages
English (en)
Inventor
Koen Hellendoorn
Matthew Baker
Francis J Carr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0213565A publication Critical patent/BR0213565A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANTICORPO DE ANTI-TNF ALFA MODIFICADO". A invenção refere-se a modificação de anticorpos reativos a fator de necrose de tumor humano alfa (TNF-alfa) para resultar em anticorpos de anti-TNF alfa que são substancialmente não imunogênicos ou menos imunogênicos do que qualquer anticorpo de origem não modificado quando usado in vivo. A invenção refere-se também a moléculas de peptídeo compreendendo epítopos de célula T das regiões V do anticorpo de origem que são modificadas por alteração de aminoácido a fim de reduzir ou eliminar os ditos epítopos de célula T.
BR0213565-5A 2001-11-12 2002-11-11 Anticorpo de anti-tnf alfa modificado BR0213565A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126858 2001-11-12
PCT/EP2002/012566 WO2003042247A2 (en) 2001-11-12 2002-11-11 Modified anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
BR0213565A true BR0213565A (pt) 2004-10-26

Family

ID=8179220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213565-5A BR0213565A (pt) 2001-11-12 2002-11-11 Anticorpo de anti-tnf alfa modificado

Country Status (17)

Country Link
US (2) US7524502B2 (pt)
EP (1) EP1448602B1 (pt)
JP (1) JP4304073B2 (pt)
KR (1) KR20050044405A (pt)
CN (1) CN1585778A (pt)
AT (1) ATE469176T1 (pt)
AU (1) AU2002351957B2 (pt)
BR (1) BR0213565A (pt)
CA (1) CA2466592A1 (pt)
DE (1) DE60236536D1 (pt)
ES (1) ES2346517T3 (pt)
HU (1) HUP0402333A3 (pt)
MX (1) MXPA04004417A (pt)
PL (1) PL369739A1 (pt)
RU (1) RU2004117915A (pt)
WO (1) WO2003042247A2 (pt)
ZA (1) ZA200404626B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7266698A (en) * 1997-04-30 1998-11-24 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
CN1898267B (zh) * 2003-11-01 2012-05-23 默克专利股份有限公司 修饰的抗cd52抗体
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
GB0425713D0 (en) 2004-11-23 2004-12-22 Baker Matthew Immunogencity testing and antibody selection methods
EP2388271A3 (en) 2005-02-03 2012-08-01 Antitope Limited Human Antibodies and Proteins
EP1869192B1 (en) * 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
WO2006124611A1 (en) * 2005-05-12 2006-11-23 Attenuon, Llc Treatment of inflammatory bowel disease (ibd) with anti-angiogenic compounds
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
SI1919951T1 (sl) * 2005-08-04 2015-05-29 Janssen Biotech, Inc. Anti-tnf-alfa protitelesa in postopki za uporabo
EP2423219B1 (en) * 2007-01-30 2015-04-29 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
WO2009014835A2 (en) 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
KR101881714B1 (ko) 2009-10-26 2018-07-24 네스텍 소시에테아노님 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법
CN102443063B (zh) * 2010-09-30 2013-10-23 成都康弘生物科技有限公司 抗TNFα的人源化Fab和人源化抗体及其用途
CN103501815B (zh) 2010-10-08 2016-09-28 希望之城公司 针对中间位的单克隆抗体框架结合界面、中间位投递系统及其使用方法
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
JP5960707B2 (ja) 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
EP3130921B1 (en) 2011-07-06 2018-09-12 Nestec S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
HK1220376A1 (zh) 2013-03-15 2017-05-05 Angelica Therapeutics, Inc. 修饰的毒素
MX2015016329A (es) * 2013-05-28 2016-07-20 Dcb Usa Llc Bloqueador de anticuerpo para la inactivacion de farmaco de proteina.
RU2556816C1 (ru) * 2014-03-12 2015-07-20 Открытое акционерное общество "Фармацевтический импорт, экспорт" (ОАО "Фармимэкс") Штамм клеток яичников китайского хомячка - продуцент рекомбинантного антитела против фактора некроза опухоли альфа человека
EP3536705A1 (en) 2014-12-05 2019-09-11 Société des Produits Nestlé S.A. Isolated soluble alpha-4 integrin, beta-7 integrin and alpha-4/beta-7 heterodimer integrin
CN105820246A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型重组抗TNFα嵌合单克隆抗体制备方法及用途
WO2016153838A1 (en) * 2015-03-20 2016-09-29 Full Spectrum Genetics, Inc. Novel anti-tnfa binding compounds and uses thereof
PE20190622A1 (es) 2016-06-02 2019-04-26 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
WO2018182635A1 (en) 2017-03-30 2018-10-04 Blonder Tongue Laboratories, Inc. Enterprise content gateway
MA49796A (fr) 2017-12-01 2020-06-03 Abbvie Inc Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
WO2020206149A2 (en) * 2019-04-05 2020-10-08 The Regents Of The University Of California Methods and compositions involving chimeric binding polypeptides
CN111909267B (zh) * 2019-05-07 2022-03-25 北京天成新脉生物技术有限公司 低免疫原性抗TNF-α人源化单克隆抗体TCX063及其应用
GB202004916D0 (en) * 2020-04-02 2020-05-20 Univ Oxford Innovation Ltd Antibodies
AU2021365528A1 (en) * 2020-10-23 2023-06-15 Hq Han Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
GB2644591A (en) * 2023-06-08 2026-04-15 Xentria Inc Methods for detecting a neutralizing antibody (NAB) against an anti-TNF alpha antibody

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2736076A1 (en) * 1991-03-18 1992-09-19 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5519000A (en) * 1994-04-01 1996-05-21 Centecor, Inc. Tumor necrosis factor inhibitors
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
EP1230269A2 (en) * 1999-11-03 2002-08-14 Maxygen, Inc. Antibody diversity generation
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU2002256624B2 (en) * 2001-02-19 2007-12-06 Merck Patent Gmbh Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity

Also Published As

Publication number Publication date
ZA200404626B (en) 2005-10-26
EP1448602B1 (en) 2010-05-26
HUP0402333A3 (en) 2007-05-02
US7524502B2 (en) 2009-04-28
ES2346517T3 (es) 2010-10-18
WO2003042247A2 (en) 2003-05-22
CN1585778A (zh) 2005-02-23
AU2002351957B2 (en) 2009-09-03
KR20050044405A (ko) 2005-05-12
US7754853B2 (en) 2010-07-13
WO2003042247A3 (en) 2004-03-11
CA2466592A1 (en) 2003-05-22
JP4304073B2 (ja) 2009-07-29
HUP0402333A2 (hu) 2005-02-28
DE60236536D1 (de) 2010-07-08
MXPA04004417A (es) 2004-08-11
US20040260069A1 (en) 2004-12-23
RU2004117915A (ru) 2005-05-10
US20060018903A1 (en) 2006-01-26
JP2005510216A (ja) 2005-04-21
ATE469176T1 (de) 2010-06-15
PL369739A1 (en) 2005-05-02
EP1448602A2 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
MXPA04004417A (es) Anticuerpo anti-tnf alfa modificado.
SI1583774T1 (sl) Postopki za preprečevanje in zdravljenje Alzheimerjeve bolezni AD
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
JP2006526414A5 (pt)
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
BRPI0418766A (pt) anticorpos e moléculas derivadas destes que se ligam às proteìnas steap-1
BR0209177A (pt) Anticorpo especìfico a tumor recombinante e uso do mesmo
DE602005016712D1 (de) Rter dna
NO995002D0 (no) Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF-<alfa>-molekyler og DNA
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
EP1461073A4 (en) PEPTIDAGONISTS FOR PROSTATE-SPECIFIC ANTIGEN AND THEIR USE
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
RU2317998C2 (ru) Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
BRPI0500311A (pt) processo de preparação de uma composição de tratamento cosmético das matérias queratìnicas, composição de tratamento cosmético das matérias queratìnicas, processos de tratamento cosmético das matérias queratìnicas, dispositivo de condicionamento de uma composição cosmética e uso de uma composição
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
CN100402551C (zh) β2-微球蛋白的抗原表位及应用
BR0311308A (pt) Briodina 1 modificada com imunogenicidade reduzida
ATE466876T1 (de) Immunogene konstrukte
BR0214567A (pt) Epìtopos de célula t em carboxipeptidase g2
DK1399482T3 (da) Bestemmelse af bone-sialoprotein i kropsvæsker til on-kologiske problemstillinger
SE0101030D0 (sv) Immunogenic cell surface proteins of helicobacter pylori
JP2002541067A (ja) 腫瘍マーカーｍｕｃ１のペプチド変異体及びその利用

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.